Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Opdivo Approved in Europe for Additional Use in Melanoma Patients
Opdivo Approved in Europe for Additional Use in Melanoma Patients
Opdivo Approved in Europe for Additional Use in Melanoma Patients
Submitted by
admin
on July 31, 2018 - 10:12am
Source:
CP Wire
News Tags:
Opdivdo
Bristol-Myers Squibb
melanoma
advanced melanoma
Europe
Headline:
Opdivo Approved in Europe for Additional Use in Melanoma Patients
snippet:
Approval makes Opdivo the only PD-1 with EC approval in adjucant setting
The indication is for both BRAF mutant and wild-type melanoma
Approval based on superior results vs Yervoy in Ph III trial
Do Not Allow Advertisers to Use My Personal information
